|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||175.01 - 177.69|
|52 Week Range||145.12 - 191.10|
|PE Ratio (TTM)||15.97|
|Forward Dividend & Yield||4.60 (2.62%)|
|1y Target Est||N/A|
Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer. Kyprolis when used with two standard of care drugs, dexamethasone and Celgene Corp's Revlimid, reduced the risk of death by 21 percent and extended survival by 7.9 months, compared with patients treated with the two drugs alone, the company said. The study, ASPIRE, tested Kyprolis, chemically known as carfilzomib, in multiple myeloma patients whose cancer had relapsed following prior treatment or did not respond to treatment.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Amgen, Inc. a score of 47. Our analysis is based on comparing Amgen, Inc. with the following peers – Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Celgene Corporation, Gilead Sciences, Inc., AbbVie, Inc., Biogen Inc., Alexion Pharmaceuticals, Inc., Roche Holding Ltd Genusssch. and Johnson & ... Read more (Read more...)
Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.
23 analysts were tracking Pfizer in November 2017. One analyst recommended a “strong buy,” while 11 analysts recommended a “buy.”
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Amgen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Amgen and Regeneron will battle in 2018 after the latter unveils cardiovascular data for its cholesterol drug Praluent.
Amgen (AMGN) announced FDA approval of its regulatory application seeking approval to expand Repatha's label to prevent heart attacks and strokes in patients with established cardiovascular disease.